-
Mashup Score: 6Multi-Gene Panel for Thrombophilia Testing in Venous Thromboembolism - 1 month(s) ago
Conventional tests for inherited thrombophilia focus on the five most-established inherited thrombophilias; i.e. deficiencies in antithrombin, protein C, and protein S, and the factor V Leiden and prothrombin G20210A variants. These tests identify thrombophilia in approximately 40% of tested patients with venous thromboembolism (VTE). Next-generation sequencing allows to detect variants in multiple coagulation-related genes, yet its clinical value for VTE remains unknown.
Source: www.jthjournal.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 11Use of antithrombotic therapy in patients with hemophilia: A selected synopsis of the EHA-ISTH-EAHAD-ESO Clinical Practice Guidance document - 3 month(s) ago
Here, we summarize the EHA-ISTH-EAHAD-ESO Clinical Practice Guidance document recommendations on antithrombotic therapy for cardiovascular indications among patients with hemophilia. This summary includes discussion on primary and secondary prevention of venous and arterial thrombosis. The guidance document considers distinct and controversial challenges presented by various clinical scenarios in this aging patient population and provides thoughtful recommendations to assist the hemophilia care provider in clinical decision-making.
Source: www.jthjournal.orgCategories: General Medicine News, Hem/OncsTweet-
Check out the selected synopsis of the recent @EHA_Hematology @ISTH @EAHAD @EAHADnews @StrokeEso79453 clinical practice guidance on managing antithrombotic therapy in patients with #hemophilia published in @JTHjournal https://t.co/NGey3l7iqB https://t.co/TMFdZHLSXm
-
-
Mashup Score: 17The evolving landscape of von Willebrand disease diagnosis - 3 month(s) ago
In their review article, O’Donnell et al. 2024 outline previous and existing challenges in the diagnosis of von Willebrand disease (VWD) and describe a potential path forward, given the clinical and phenotypic heterogeneity observed in patients with von Willebrand factor (VWF) levels between 30 and 50 IU/dL. VWD is a complex bleeding disorder characterized by deficiencies in VWF, a protein crucial for blood clotting.
Source: www.jthjournal.orgCategories: General Medicine News, Hem/OncsTweet-
Commentary in @JTHjournal by Brooke Sadler on the issue of how individuals with VWF levels of 30-50% should be managed. https://t.co/6TNALNpy2W #VWF #VWD #Willebrand https://t.co/IdhUXDgLa8
-
-
Mashup Score: 8Acquired Hemophilia A: A Narrative Review and Management Approach in the Emicizumab Era - 3 month(s) ago
Acquired Hemophilia A (AHA) is a rare bleeding disorder caused by inhibitory autoantibodies to factor VIII (FVIII). The goals of treatment are two-fold, namely immunosuppressive therapy (IST) to eradicate the inhibitor and hemostatic management to control bleeding. Emicizumab, a bispecific antibody that acts as a factor VIIIa (FVIIIa) mimetic, has seen growing use in AHA following its approval for congenital hemophilia A (cHA). This review provides an overview of the epidemiology, pathophysiology, diagnosis, and treatment of AHA.
Source: www.jthjournal.orgCategories: General Medicine News, Hem/OncsTweet-
RT @flora_peyvandi: #Acquired Hemophilia A: A Narrative Review and Management Approach in the #Emicizumab Era https://t.co/nkC9pIeMaX
-
-
Mashup Score: 9Preferences of pregnant women for postpartum thromboprophylaxis: the bicentric PREFER-PostPartum study - 4 month(s) ago
Clinical guidelines for postpartum thromboprophylaxis differ due to its uncertain effect and varying preferences of experts. Women’s preferences for postpartum thromboprophylaxis are unknown, although they may inform practices and future research.
Source: www.jthjournal.orgCategories: General Medicine News, Oncologists1Tweet-
Preferences of pregnant women for postpartum thromboprophylaxis: the bicentric PREFER-PostPartum study @JTHjournal https://t.co/gVwp1GYAaP
-
-
Mashup Score: 7
von Willebrand factor (VWF)-R1205H variant (Vicenza) results in markedly enhanced VWF clearance in humans that has been shown to be largely macrophage-mediated. However, the biological mechanisms underlying this enhanced clearance remain poorly understood.
Source: www.jthjournal.orgCategories: General Medicine News, Oncologists1Tweet-
R1205H (Vicenza) causes conformational changes in the von Willebrand factor D′D3 domains and enhances von Willebrand factor binding to clearance receptors LRP1 and SR-AI @JTHjournal https://t.co/HWJSSQTly8
-
-
Mashup Score: 5An integrated multitool analysis contributes elements to interpreting unclassified factor IX missense variants associated with hemophilia B - 4 month(s) ago
Dissection of genotype–phenotype relationships in hemophilia B (HB) is particularly relevant for challenging (mild HB) or for HB-associated but unclassified factor (F)IX missense variants.
Source: www.jthjournal.orgCategories: General Medicine News, Oncologists1Tweet-
An integrated multitool analysis contributes elements to interpreting unclassified factor IX missense variants associated with hemophilia B @JTHjournal https://t.co/oMfry7JUJ1
-
-
Mashup Score: 6Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A - 4 month(s) ago
Acquired hemophilia A (AHA) is an autoimmune bleeding disorder caused by neutralizing antibodies against coagulation factor VIII. Immunosuppressive therapy (IST) is standard of care to eradicate autoantibody production and protect from further bleeding but carries a risk of severe infection and mortality in frail patients with AHA. Recently, emicizumab has been studied for its potential to reduce the need for early and aggressive IST.
Source: www.jthjournal.orgCategories: General Medicine News, Hem/OncsTweet-
RT @flora_peyvandi: #Emicizumab versus immunosuppressive therapy for the management of #acquired hemophilia A https://t.co/sOxwX9KTV7
-
-
Mashup Score: 6
The currently approved direct oral anticoagulants (DOACs) are increasingly used in clinical practice. Although serious bleeding risks are lower with DOACs than with vitamin K antagonists, bleeding remains the most frequent side effect. Andexanet alfa and idarucizumab are the currently approved specific reversal agents for oral factor (F)Xa inhibitors and dabigatran, respectively. Our prior guidance document was published in 2016, but with more information available on the utility and increased use of these reversal agents and other bleeding management strategies, we have updated this International Society on Thrombosis and Haemostasis guidance document on DOAC reversal.
Source: www.jthjournal.orgCategories: General Medicine News, Hem/OncsTweet-
RT @flora_peyvandi: #Reversal of direct oral #anticoagulants: guidance from the #SSC of the ISTH https://t.co/BT6vZFWYOg
-
-
Mashup Score: 6Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A - 5 month(s) ago
Acquired hemophilia A (AHA) is an autoimmune bleeding disorder caused by neutralizing antibodies against coagulation factor VIII. Immunosuppressive therapy (IST) is standard of care to eradicate autoantibody production and protect from further bleeding but carries a risk of severe infection and mortality in frail patients with AHA. Recently, emicizumab has been studied for its potential to reduce the need for early and aggressive IST.
Source: www.jthjournal.orgCategories: General Medicine News, Hem/OncsTweet-
RT @flora_peyvandi: #Emicizumab versus immunosuppressive therapy for the management of #acquired hemophilia A https://t.co/sOxwX9KTV7
-
RT @flora_peyvandi: #Multi -Gene Panel for #Thrombophilia Testing in Venous Thromboembolism https://t.co/OK6JQ6OKEB